Drug Profile
VE 303
Alternative Names: VE-303Latest Information Update: 30 Nov 2023
Price :
$50
*
At a glance
- Originator Vedanta Biosciences
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Clostridium difficile infections; Hepatic encephalopathy
Most Recent Events
- 28 Nov 2023 Vedanta Biosciences has patent protection for cover compositions of clostridia bacterial species in European Union
- 10 Nov 2023 Efficacy, adverse event and pharmacokinetics data from phase II trial in Hepatic encephalopathy presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 08 May 2023 Vedanta Biosciences plans a pivotal phase III RestoratiVE303 trial for Clostridium difficile infections (Recurrent, Prevention) in the coming months